aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
By Dr. Matthew Watson
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.
Related Post
- Better Choice Company Announces Strategic Investment of $2.7 Million, Co-Lead by Insiders and Management - January 19th, 2021
- TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review - January 19th, 2021
- Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants - January 19th, 2021
- XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy - January 19th, 2021
- Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial - January 19th, 2021
- Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting - January 19th, 2021
- Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel - January 19th, 2021
- Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience - January 19th, 2021
- NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member - January 19th, 2021
- Novan Provides Enrollment Update and Announces New Corporate Headquarters - January 19th, 2021
- Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - January 19th, 2021
- Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant - January 19th, 2021
- Bespoke Extracts Increases Conversion Price of Outstanding Discount Convertible Debentures - January 19th, 2021
- Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer - January 19th, 2021
- Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - January 19th, 2021
- Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters - January 19th, 2021
- Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option - January 19th, 2021
- VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) - January 19th, 2021
- Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference - January 19th, 2021
- Agenus to Participate in B. Riley Securities' Oncology Investor Conference - January 19th, 2021
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Qilian International Holding Group Limited Announces Pricing of Initial Public Offering - January 12th, 2021
- Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - January 12th, 2021
- Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common... - January 12th, 2021
- Addex to Present at the Baader Helvea Swiss Equities Conference - January 12th, 2021
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 - January 12th, 2021
- Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study - January 12th, 2021
- BetterLife Provides Shareholder Update and 2021 Product Development Roadmap - January 12th, 2021
- Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 - January 12th, 2021
- Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation - January 12th, 2021
- Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities - January 12th, 2021
- Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate - January 12th, 2021
- ProMIS Neurosciences Announces Strategic Priorities for 2021 - January 12th, 2021
- Adamas to Present at Upcoming H.C. Wainwright Conference - January 5th, 2021
- Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference - January 5th, 2021
- Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference - January 5th, 2021
- Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team - January 5th, 2021
- Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference - January 5th, 2021
- Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group - January 5th, 2021
- Ligature Therapeutics Launches, Raises USD $6M in Seed Financing - January 5th, 2021
- Radius Health Announces Change to its Board of Directors - January 5th, 2021
- Franciosi Consulting Reviewing the Science and History of Psychedelic Drug Use for Treating Depression, Anxiety and Addiction - January 5th, 2021
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - January 5th, 2021
- Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development - January 5th, 2021
- Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung... - January 5th, 2021
- Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021 - January 5th, 2021
- Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - January 5th, 2021
- ViGeneron signs global collaboration agreement for ophthalmic gene therapy development - January 5th, 2021
- Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries - January 5th, 2021
- AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - January 5th, 2021
- Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference - January 5th, 2021
- Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine - January 5th, 2021
- Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market - January 3rd, 2021
- Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - January 3rd, 2021
- VAXIL Provides Update on USAMRIID and Oral Experiments - January 3rd, 2021
- Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19 - January 3rd, 2021
- Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - January 3rd, 2021
- Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets - January 3rd, 2021
- Eve & Co Announces Share Consolidation - January 3rd, 2021
- Total number of shares and voting rights in Zealand Pharma at December 31, 2020 - January 3rd, 2021
- Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study - January 3rd, 2021
- Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia - January 3rd, 2021
- Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) - January 3rd, 2021
- Avicanna Announces Exercise and Closing of Over-Allotment Option - January 3rd, 2021
- Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete... - January 3rd, 2021
- Tauriga Sciences Inc. Approved to be Corporate Exhibitor at 2021 CTIC Capital Pre-J.P. Morgan Healthcare Investment Summit January 9th-10th, 2021 - January 3rd, 2021
- Teligent, Inc. Announces Third Quarter 2020 Results - January 3rd, 2021
- Draft Top Tool Reviews - Go Topless! – Product Review by Mike Vaughn - January 3rd, 2021
- Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants - January 3rd, 2021
- Franciosi Consulting Assessing New Potential Treatments for Asthma and COPD - December 30th, 2020
- Nicox’s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China - December 30th, 2020
- Change in Number of Shares and Votes in Immunicum AB (publ) - December 30th, 2020
- Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK - December 30th, 2020
- Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021 - December 30th, 2020
- Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors - December 30th, 2020
- Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy... - December 30th, 2020
- Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B - December 30th, 2020
- Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference - December 30th, 2020
Global News Feed
Comments Off on aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications |
January 5th, 2021
This author published 3424 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research